Review of a decade of progress in T2D cardiovascular management chronicles the transformative impact of GLP-1 drugs and SGLT2 inhibitors on heart outcomes.
Key findingReview of a decade of progress in T2D cardiovascular management chronicles the transformative impact
What the researchers found
Review of a decade of progress in T2D cardiovascular management chronicles the transformative impact of GLP-1 drugs and SGLT2 inhibitors on heart outcomes.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Review covers the decade of CVOTs since 2015. Multiple trials with tens of thousands of patients demonstrating reduced MACE, CV death, and heart failure.
How the study worked
In publication.
Who was studied
Patients with type 2 diabetes across multiple large-scale cardiovascular outcome trials
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.
Frontiers in endocrinology, 16, 1605746
Citation
Aristizábal-Colorado, David; Corredor-Rengifo, David; Sierra-Castillo, Santiago; López-Corredor, Carolina; Vernaza-Trujillo, David-Alexander; Weir-Restrepo, Danilo; Izquierdo-Condoy, Juan S; Ortiz-Prado, Esteban; Rico-Fontalvo, Jorge; Gómez-Mesa, Juan-Esteban; Abreu-Lomba, Alin; Rivera-Martínez, Wilfredo-Antonio. (2025). A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.. Frontiers in endocrinology, 16, 1605746. https://doi.org/10.3389/fendo.2025.1605746